Bioprocessing

UAE to Lead Affordable CAR-T Therapy with New Biomanufacturing Hub
Biotech & Bioprocessing UAE to Lead Affordable CAR-T Therapy with New Biomanufacturing Hub

In a groundbreaking initiative, Burjeel Holdings is joining forces with Caring Cross to establish advanced biomanufacturing facilities dedicated to chimeric antigen receptor (CAR)-T cell therapies in the United Arab Emirates (UAE). This collaboration aims to revolutionize the production and

How Will INCOG's $75M Expansion Impact Sterile Injectables?
Biotech & Bioprocessing How Will INCOG's $75M Expansion Impact Sterile Injectables?

INCOG, a contract development and manufacturing organization (CDMO), recently made a substantial investment to expand its capabilities in the sterile injectables sector. In February 2024, the company committed $75 million to install an Optima syringe and cartridge filling line, projected to be GMP

Recce Pharmaceuticals Secures $15.8M to Advance Phase 3 Trials
Research & Development Recce Pharmaceuticals Secures $15.8M to Advance Phase 3 Trials

Recce Pharmaceuticals, a Sydney-based biotechnology company, has successfully raised A$15.8 million to advance its groundbreaking anti-infective drugs into Phase 3 trials. This funding was obtained through a combination of private placement and an entitlement offer. Recce's synthetic

How Is Tango Therapeutics Navigating a Challenging Biotech Market?
Research & Development How Is Tango Therapeutics Navigating a Challenging Biotech Market?

Tango Therapeutics, a biotechnology company specializing in cancer treatments, has taken significant measures to address the challenging financial landscape. Recently, the company announced layoffs affecting approximately 20% of its workforce, a strategic move designed to extend its cash runway. As

Is Leadership Reshaping the Future of Biopharma CDMOs?
Biotech & Bioprocessing Is Leadership Reshaping the Future of Biopharma CDMOs?

The biopharmaceutical sector has witnessed significant changes in leadership roles within major Contract Development and Manufacturing Organizations (CDMOs), driving strategic growth and development. The appointment of seasoned leaders plays a crucial role in strengthening the research,

How Will Landmark Bio Shape Artis Biosolutions' Future?
Biotech & Bioprocessing How Will Landmark Bio Shape Artis Biosolutions' Future?

Artis Biosolutions' acquisition of Landmark Bio marks a strategic move designed to bolster cell and gene therapy (CGT) manufacturing capabilities. Landmark Bio, founded by Harvard University, MIT, Fujifilm Diosynth Biotechnologies, Alexandria Real Estate Equities, and Cytiva, has been a key

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later